Novartis Scraps Another Drug Study. Why the Stock Is Holding Steady. Novartis Scraps Another Drug Study. Why the Stock Is Holding Steady. · Barrons.com · Sedat Suna/Getty Images Mackenzie Tatananni Fri, October 16, 2026 at 5:03 PM EDT 3 min read NVS +0.16% GS -1.12% NVS +0.16% ^GSPC -1.09% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Novartis shelves a study for Fabhalta in patients with a serious kidney-disease complication, adding to a growing list of clinical setbacks.
